Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A regimen of daily, low-dose aspirin failed to produce a significant reduction in the incidence of dementia or cognitive impairment in ASCEND, a randomized, multicenter trial with more than 15,000 people with diabetes followed for an average of more than 9 years, but the results hinted at enough of a benefit to warrant further study, some experts said.
"The question remains open," said Jane Armitage, MBBS, FRCP, as she presented the findings at the American Heart Association scientific sessions. "The rate ratios suggest some benefit. It's encouraging," added Armitage, professor of clinical trials and epidemiology at Oxford (England) University.
The study tallied dementia outcomes three different ways: It applied a narrow definition that relied on a specific diagnosis of dementia in a person's EHR or in their death record. (Armitage and her associates tracked outcomes for 99% of the enrolled participants by linking to their U.K. national health records and death records.)
www.medscape.com
"The question remains open," said Jane Armitage, MBBS, FRCP, as she presented the findings at the American Heart Association scientific sessions. "The rate ratios suggest some benefit. It's encouraging," added Armitage, professor of clinical trials and epidemiology at Oxford (England) University.
The study tallied dementia outcomes three different ways: It applied a narrow definition that relied on a specific diagnosis of dementia in a person's EHR or in their death record. (Armitage and her associates tracked outcomes for 99% of the enrolled participants by linking to their U.K. national health records and death records.)
ASCEND: Hint of Dementia Protection With Aspirin in T2D
Daily low-dose aspirin failed to produce significant reduction of dementia or cognitive impairment in a randomized trial, but there was a hint of benefit that warrants further study, experts say.
www.medscape.com
